Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TransCode TherapeuticsRNAZ -3.61%30 3-Year EPS without NRI Growth Rate is 96.80% as of Jun. 2026, which is 51% above its 10-year median of 64.15. GuruFocus rates RNAZ with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,157 Biotechnology companies, TransCode Therapeutics ranks better than 98.53% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 96.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 83.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 7 years, the highest 3-Year average EPS without NRI Growth Rate of TransCode Therapeutics was 96.80% per year. The lowest was -232.40% per year. And the median was 64.15% per year.
TransCode Therapeutics (NAS:RNAZ) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
TransCode Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
RNAZ vs VRAX, OGEN, ONCO: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, TransCode Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransCode Therapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransCode Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where TransCode Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
TransCode Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 96.80% mean?
TransCode Therapeutics (RNAZ) has a 3-Year EPS without NRI Growth Rate of 96.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for TransCode Therapeutics and its competitors. This is 51% above median its historical median of 64.15. According to the industry distribution chart, TransCode Therapeutics ranks #17 out of 1157 companies in the Biotechnology industry, placing it in the top 1.5%.
Is TransCode Therapeutics' 3-Year EPS without NRI Growth Rate too high?
TransCode Therapeutics' current 3-Year EPS without NRI Growth Rate of 96.80% is 51% above median its 10-year median of 64.15. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.90. TransCode Therapeutics' value of 96.80% is 508.8% above this industry median. Based on the distribution chart, TransCode Therapeutics ranks #17 out of 1157 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, TransCode Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' 3-Year EPS without NRI Growth Rate compare to VRAX and OGEN?
According to the Biotechnology industry distribution chart, TransCode Therapeutics ranks #17 out of 1157 companies for 3-Year EPS without NRI Growth Rate. This places TransCode Therapeutics in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 15.90. TransCode Therapeutics' value of 96.80% is 508.8% above this benchmark. While the company's 10-year median is 64.15 vs. the industry median of 15.90, TransCode Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.90, based on 1,157 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransCode Therapeutics's current 3-Year EPS without NRI Growth Rate of 96.80% is 508.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for TransCode Therapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransCode Therapeutics's current 3-Year EPS without NRI Growth Rate is 96.80%, which is 51% above median its own 10-year median of 64.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current 3-Year EPS without NRI Growth Rate of 96.80%. The current 3-Year EPS without NRI Growth Rate is 96.80%, which is 51% above median its 10-year median of 64.15 and 508.8% above the Biotechnology industry median of 15.90. TransCode Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current 3-Year EPS without NRI Growth Rate is 96.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
30GF Score
Get the complete analysis for RNAZ
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNAZ has been successfully added to your 
